Jazz launches Defitelio at €426 a vial
This article was originally published in Scrip
Executive Summary
Jazz Pharmaceuticals has begun the launch of the orphan drug Defitelio (defibrotide) in Europe, starting with Germany and Austria. The product was granted EU marketing authorization under exceptional circumstances for the treatment of severe hepatic veno-occlusive disease (sVOD) in hematopoietic stem cell transplantation (HSCT) therapy, and is indicated for patients over one month of age.